InBrain Pharma Announces the Appointment of Dr Véronique Foutel as CEO
Retrieved on:
Tuesday, February 27, 2024
Mental Health, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DBV Technologies, Hospital, Pharmacy, CHU, Dopamine, Growth, Neurological disorder, DSM-IV codes, Entrepreneurship, Pharmaceutical industry, Prevalence, Parkinson's disease, Headquarters, Medicine, Patient, Disease, CSO, Brain
InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
Key Points:
- InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
- Dr. Matthieu Fisichella, co-founder, and current CEO since 2018, will remain highly committed to InBrain Pharma and become Chief Science Officer.
- ," says Véronique Foutel, CEO of InBrain Pharma.
- "I am delighted to hand over the reins to Véronique, whose appointment comes at a critical time for InBrain Pharma.